volociximab

DRUG5 trials

Sponsors

Jonsson Comprehensive Cancer Center, Abbott, AbbVie (prior sponsor, Abbott), Facet Biotech, Ophthotech Corporation

Conditions

Age-related Macular DegenerationLung CancerOvarian CancerPancreatic CancerPeritoneal NeoplasmsStage IV Melanoma

Phase 1

A Phase 1 Ascending and Parallel Group Trial to Establish the Safety, Tolerability and Pharmacokinetics Profile of Volociximab (Alpha 5 Beta 1 Integrin Antagonist) in Subjects With Neovascular Age- Related Macular Degeneration

CompletedNCT00782093

Ophthotech CorporationAge-related Macular Degeneration

Start: 2008-10-31End: 2012-06-30Updated: 2024-02-21

Phase 2

Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Jonsson Comprehensive Cancer CenterLung Cancer

Start: 2005-07-31Updated: 2013-12-19

A Study of Volociximab in Metastatic Melanoma

TerminatedNCT00369395

AbbottStage IV Melanoma

Start: 2006-12-31End: 2008-03-31Updated: 2012-04-27

A Study of Volociximab in Combination With Gemcitabine in Metastatic Pancreatic Cancer

CompletedNCT00401570

AbbVie (prior sponsor, Abbott)Pancreatic Cancer

Start: 2005-03-31End: 2008-06-30Updated: 2013-01-30

A Phase 2, Single-Arm Study of Volociximab Monotherapy in Subjects With Platinum-Resistant Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer

TerminatedNCT00516841

Facet BiotechOvarian Cancer, Peritoneal Neoplasms

Start: 2007-08-31End: 2008-04-30Updated: 2012-08-23